342 related articles for article (PubMed ID: 31332522)
41. Claudin-18 is an early-stage marker of pancreatic carcinogenesis.
Tanaka M; Shibahara J; Fukushima N; Shinozaki A; Umeda M; Ishikawa S; Kokudo N; Fukayama M
J Histochem Cytochem; 2011 Oct; 59(10):942-52. PubMed ID: 21832145
[TBL] [Abstract][Full Text] [Related]
42. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
Rogers JE; Ajani JA
Curr Opin Oncol; 2024 Jul; 36(4):308-312. PubMed ID: 38726797
[TBL] [Abstract][Full Text] [Related]
43. Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis.
Zhou B; Flodby P; Luo J; Castillo DR; Liu Y; Yu FX; McConnell A; Varghese B; Li G; Chimge NO; Sunohara M; Koss MN; Elatre W; Conti P; Liebler JM; Yang C; Marconett CN; Laird-Offringa IA; Minoo P; Guan K; Stripp BR; Crandall ED; Borok Z
J Clin Invest; 2018 Mar; 128(3):970-984. PubMed ID: 29400695
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
45. Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma.
Espinoza JA; Riquelme I; Sagredo EA; Rosa L; García P; Bizama C; Apud-Bell M; Leal P; Weber H; Benavente F; Vargas S; Romero D; Kalergis AM; Roa JC
Histopathology; 2019 Mar; 74(4):597-607. PubMed ID: 30565710
[TBL] [Abstract][Full Text] [Related]
46. The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications.
Heckl SM; Wiesener V; Behrens HM; Ulase D; Krüger S; Röcken C
Gastric Cancer; 2019 Nov; 22(6):1130-1142. PubMed ID: 30989432
[TBL] [Abstract][Full Text] [Related]
47. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells.
Ito T; Kojima T; Yamaguchi H; Kyuno D; Kimura Y; Imamura M; Takasawa A; Murata M; Tanaka S; Hirata K; Sawada N
J Cell Biochem; 2011 Jul; 112(7):1761-72. PubMed ID: 21381080
[TBL] [Abstract][Full Text] [Related]
48. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes.
Kayikcioglu E; Yüceer RO
Medicine (Baltimore); 2023 Feb; 102(6):e32882. PubMed ID: 36820561
[TBL] [Abstract][Full Text] [Related]
49. Ultrasensitive Gastric Cancer Circulating Tumor Cellular
Fan L; Chong X; Zhao M; Jia F; Wang Z; Zhou Y; Lu X; Huang Q; Li P; Yang Y; Hu Z; Li Q; Zhang X; Shen L
Anal Chem; 2021 Jan; 93(2):665-670. PubMed ID: 33314914
[TBL] [Abstract][Full Text] [Related]
50. CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma.
Hur JY; Min KW; Noh YK; Won YW; Yeo Y; Kim DH; Son BK; Kwon MJ; Pyo JS
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38639279
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype.
Oue N; Sentani K; Sakamoto N; Yasui W
Cancer Sci; 2015 Aug; 106(8):951-8. PubMed ID: 26033320
[TBL] [Abstract][Full Text] [Related]
52. Functional Analysis of Gastric Tight Junction Proteins in
Stein L; Brunner N; Amasheh S
Membranes (Basel); 2022 Jul; 12(8):. PubMed ID: 35893449
[TBL] [Abstract][Full Text] [Related]
53. Development and comparison of three
Hu G; Zhu W; Liu Y; Wang Y; Zhang Z; Zhu S; Duan W; Zhou P; Fu C; Li F; Huo L
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2634-2644. PubMed ID: 35347439
[TBL] [Abstract][Full Text] [Related]
54. Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer.
Kim SR; Shin K; Park JM; Lee HH; Song KY; Lee SH; Kim B; Kim SY; Seo J; Kim JO; Roh SY; Kim IH
J Gastric Cancer; 2020 Dec; 20(4):408-420. PubMed ID: 33425442
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of intestinal claudins in high-risk synchronous and metachronous multiple gastric epithelial neoplasias after initial endoscopic submucosal dissection.
Semba S; Hasuo T; Satake S; Nakayama F; Yokozaki H
Pathol Int; 2008 Jun; 58(6):371-7. PubMed ID: 18477216
[TBL] [Abstract][Full Text] [Related]
56. CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
Luo J; Chimge NO; Zhou B; Flodby P; Castaldi A; Firth AL; Liu Y; Wang H; Yang C; Marconett CN; Crandall ED; Offringa IA; Frenkel B; Borok Z
Int J Cancer; 2018 Dec; 143(12):3169-3180. PubMed ID: 30325015
[TBL] [Abstract][Full Text] [Related]
57. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC).
Xu B; Liu F; Liu Q; Shi T; Wang Z; Wu N; Xu X; Li L; Fan X; Yu L; Liu B; Wei J
J Gastrointest Oncol; 2020 Dec; 11(6):1431-1439. PubMed ID: 33457012
[TBL] [Abstract][Full Text] [Related]
58. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
[TBL] [Abstract][Full Text] [Related]
59. Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.
Chen XL; Chen XZ; Wang YG; He D; Lu ZH; Liu K; Zhang WH; Wang W; Li CC; Xue L; Zhao LY; Yang K; Liu JP; Zhou ZG; Hu JK; Mo XM
Oncotarget; 2016 Sep; 7(38):62049-62069. PubMed ID: 27557490
[TBL] [Abstract][Full Text] [Related]
60. Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer.
Nam KH; Lee BL; Park JH; Kim J; Han N; Lee HE; Kim MA; Lee HS; Kim WH
Pathobiology; 2013; 80(2):87-94. PubMed ID: 23038627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
